Delcath Systems Analyst Report by BrokerBank Securities, Inc.

Loading...
Loading...

NEW YORK, March 24, 2014 /PRNewswire/ -- Delcath Systems, Inc. DCTH is a specialty pharmaceutical and medical device company mainly focused on the treatment of primary and metastatic liver cancers.

Liver cancer is the sixth most common cancer in the world with nearly 780,000 new cases diagnosed each year. It is estimated by Global Industry Analysts (GIA) that the potential market for liver cancer worldwide will exceed $2 billion by the year 2015.

Primary liver cancer (hepatocellular carcinoma, or HCC) originates in the liver or biliary tissue and is usually associated with hepatitis-B, hepatitis-C, high levels of alcohol consumption, aflatoxin, cigarette smoking, exposure to industrial pollutants, etc. Meanwhile, metastatic liver cancer is characterized by microscopic cancer cell clusters that detach from the primary site of disease and travel via the blood stream and lymphatic system into the liver, where they grow into new tumors. In the US, the latter is the more common type of liver cancer, while the former is more common in less developed regions of the world where higher levels of hepatitis-B and hepatitis-C are reported. As such, HCC is one of the most prevalent and lethal forms of cancer.

A full in-depth analyst report on DCTH that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/DCTH-AnalystReport

copy and paste may be required

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. An outsourced research services provider represented by Michael Maggi, Chartered Financial Analyst, provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC and BrokerBank Securities, Inc. are not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Maggi, Chartered Financial Analyst. This press release is being issued to inform shareholder and potential investors.

Note: Small Cap Street, LLC and BrokerBank Securities, Inc. do not engage in the business of giving price target or buy or sell recommendations. The above report is not the opinion of Small Cap Street, LLC and BrokerBank Securities, Inc.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapir.com. For any urgent concerns or inquiries, please contact us at admin@smallcapir.com.

NO WARRANTY OR LIABILITY ASSUMED

DCTH has not compensated Small Cap Street, LLC, BrokerBank Securities, Inc, or Michael Maggi, Chartered Financial Analyst for the creation or dissemination of this report. Small Cap Street, LLC and BrokerBank Securities, Inc, is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Small Cap Street, LLC and BrokerBank Securities, Inc. whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC and BrokerBank Securities, Inc. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC and BrokerBank Securities, Inc. do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Small Cap Street, LLC is the party responsible for hosting the full analyst report on smallcapstreet.com. BrokerBank Securities in the party responsible for issuing the press release and Michael Maggi, Chartered Financial Analyst, is the author of research report. Michael Maggi, Chartered Financial Analyst has been compensated one hundred dollars for right to disseminate this report. Information in this release is fact checked and produced on a best efforts basis by Michael Maggi, Chartered Financial Analyst.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...